Vendor Intelligence Report: ZePeptide

Published 3 Jul 2026. 29-page investigative report on who is behind ZePeptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

ZePeptide is a mixed chemistry record wrapped in a high-friction identity story. Across 49 Finnrick lab tests, ZePeptide’s overall pass rate is 78% (38 pass / 11 fail). The catalog is uneven rather than uniformly bad: Retatrutide and GHK-Cu are the defensible end of the tested record, while TB-500 and Tesamorelin are the clearest weak spots; ratings also fall under stricter grading where process control looks thinner.

The OSINT record is less forgiving than the best lab results. ChemicalBook supplier records point to a Shijiazhuang operator that does not support the brand’s long-tenure marketing, and archived web content shows experience claims shifting as the domain footprint changes. A personal Gmail contact, Western-facing staff names, and unverifiable scientific personas sit between buyers and the actual Chinese corporate anchor.

The infrastructure trail matters for anyone deciding whether to send money. ZePeptide’s original .com was observed on registrar-level hold, a replacement .net was already live, a blank .org shared a technical identifier, and a hyphenated domain displayed enterprise information for a separate Chinese company. Payment rails seen in the report are crypto and wire, while buyer reports describe domain-switch pressure, post-payment silence, and COAs that may verify as documents without matching shipped lots.

Inside the full report:

  • Per-product Finnrick interpretation, methodology-divergence charts, and Appendix A laboratory data for all 6 tested products
  • ChemicalBook corporate records tying the brand to a Shijiazhuang supplier and testing the long-history claim
  • Domain timeline covering the suspended .com, replacement .net, blank .org, hyphenated domain, and peptide.mom lead
  • Personnel and alias analysis using archived staff photos, filenames, emails, and unverifiable leadership profiles
  • Payment, fulfillment, Reddit-report, and COA batch-correlation risk assessment
  • Re-verification identifiers and watch items including the shared Google Analytics ID, emails, phone numbers, and TikTok account

Risk assessment

  • Misrepresented corporate history and personnel-credential risk — high: ChemicalBook records indicate a 2020 Shijiazhuang operator and zepeptide.com was registered in 2025, while ZePeptide markets 17+ years and unverifiable Western/scientific leadership.
  • Corporate-impersonation and brand-confusion risk — high: ze-peptide.com displays Nanjing Peptide Industry Biotechnology details without a verified affiliation; multiple ZePeptide domains and no stable canonical channel expose buyers to copycat/confusion.
  • Irreversible payment and fulfillment-loss risk — high: zepeptide.net lists Bitcoin, USDT, USDC, ETH and wire transfer; Reddit reports describe $450/$569 post-payment ghosting or repeat-payment demands.
  • COA and batch-correlation risk — high: Buyer reports state Janoshik COAs did not match shipped lot/batch numbers, so documents may not certify the vial received.
  • Product-specific quality risk: TB-500, Tesamorelin and BPC-157 — high: Finnrick rates TB-500 45.44%, Tesamorelin 54.73% and BPC-157 55.89%, materially weaker than ZePeptide's Retatrutide/GHK-Cu results.
  • Operational continuity risk — high: zepeptide.com entered clientHold on June 11, 2026; zepeptide.net was registered April 14, 2026 and operated as a replacement amid a broader multi-domain network.
  • Unverified GMP/regulatory-assurance risk — medium: The supplied record did not verify GMP certification or regulatory authorization; the quality-assurance page was not archived.